Omniscope, a leader in decoding the human immune system, is proud to announce the publication of a landmark study in Annals of Oncology, detailing a collaborative effort with Centro Nacional de Análisis Genómico (CNAG), IRB Barcelona, and Sant Joan de Déu Hospital to decode immune response in a <1-year-old patient with renal rhabdoid tumor, a rare and aggressive pediatric cancer.
Using Omniscope’s proprietary immune profiling platform, researchers tracked the dynamics of T cells across time and compartments (tumor and blood), identifying tumor-reactive T cells with high precision. These insights not only informed the patient's immunotherapy response but also laid the foundation for designing second-line, personalized cell therapies using TCR-T engineering.
“Personalized cell therapies are now within reach,” said Prof. Holger Heyn, Omniscope Co-founder and Chief Scientific Officer and ICREA Professor at the CNAG. “In this study, we demonstrate how tumor-reactive T cells can be identified both within the tumor and in the bloodstream. Combined with recent advances in engineering a patient’s own cells — both in vitro and in vivo — this work marks a significant step forward toward the next leap in precision oncology.”
By combining liquid biopsy with large-scale TCR sequencing, the team successfully demonstrated that real-time immune monitoring can guide and predict therapy outcomes — particularly in diseases where standard treatments fall short.
“Cancer and other immune-mediated diseases require scalable, personalized solutions,” added Vijay Vaswani, Omniscope Co-founder and CEO. “By modeling response to therapy through proprietary immune data and validated mRNA platforms,Omniscope helps drastically reduce the cost, time and complexity of cell therapy development. This approach can extend across immune-mediated diseases, transforming both patient care and drug discovery.”
This study provides one of the first in-depth immune monitoring cases in pediatric rhabdoid cancer and underscores the potential of in silico and mRNA-enabled designs to advance personalized therapies for rare and challenging diseases.
Read the full publication in Annals of Oncology: https://doi.org/10.1016/j.annonc.2025.05.530
ABOUT OMNISCOPE
Omniscope is a techbio company specializing in advancedimmune profiling technologies. Its proprietary AI-enabled platforms enabledeep, high-resolution analysis of immune cell dynamics, providing criticalinsights for personalized medicine, biomarker discovery, and the development ofnovel immunotherapies.
Image shown: From left to right, Dr. Alexandra Avgustinova, Dr. Inés Sentís Carreras, and Prof. Holger Heyn, Omniscope Co-founder and Chief Scientific Officer, in the lab at IRB Barcelona.
